Email : info@nexusalliancebiopharma.com
Contact : (321) 445-1969

Clinical and safety evaluation of Brillia in patients with Anxiety Disorder

Background:Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental disorders in children. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD will have trouble paying attention, controlling impulsive behaviors, or be overly active. The hallmarks are hyperactivity, impulsivity, and inattention that are beyond reasonable developmental expectations for a child's age. The science behind Brillia is based on a new way to combine homeopathy and antibody science. The active ingredient of Brillia, Lapine S-100 immune globulin, is produced using antibodies to the brainspecific S-100 protein (S-100B). This protein is an essential regulator of many different intracellular and extracellular brain processes, e.g., various enzyme activities, calcium homeostasis, communication between neurons, etc. Thus, the clinical study of the efficacy of Brillia for Children for the treatment of anxiety disorders, disturbances of behavior, and attention, accompanied by increased excitability, irritability, and hyperactivity, are very important and promising. To determine the efficacy of Brillia for Children for the treatment of anxiety disorders, disturbances of behavior, and attention, accompanied by increased excitability, irritability, and hyperactivity in children, two clinical studies were carried out.

Methods: A double-blind, randomized placebo-controlled study of Brillia evaluating clinical efficacy and safety for children with attention deficit hyperactivity disorder was conducted. Prior to inclusion in the study, the patients or their legal guardians were provided with information about the study and signed an informed consent form. Patient information collected during the study is strictly confidential.

Download Pdf